2012: CRADA for engineered peripheral blood autologous T cell therapeutics (eACT) for hematological and solid cancersa2013/5: Research collaboration for engineered peripheral blood autologous T cell therapeutics (eACT) for hematological and solid cancersa2012/5: Research collaboration for engineered peripheral blood autologous T cell therapeutics (eACT) for hematological and solid cancersa2016: CRADA for fully human anti-CD19 CAR product for B-cell lymphomas and leukemias. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.